Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jose Nativi

Showing results (1-10 of 80) with videos related to

Pageof 8
Sort By:
Circulation. Heart Failure|February 17, 2018
Serum Transthyretin: Predictor of Amyloidosis Outcomes?Jose Nativi-Nicolau
Current Opinion in Cardiology|July 18, 2018
Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common typesJose Nativi-Nicolau, Mathew S Maurer
Heart Failure Clinics|July 1, 2014
Current therapeutic approach in heart failure with preserved ejection fractionJose Nativi-Nicolau, John J Ryan, James C Fang
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|March 30, 2022
Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid CardiomyopathyMark H Rozenbaum, Diana Tran, Rahul Bhambri, et al.
Current Opinion in Cardiology|April 2, 2014
Pharmacologic therapies for acute cardiogenic shockJose Nativi-Nicolau, Craig H Selzman, James C Fang, et al.
JACC. Heart Failure|July 13, 2020
Utility of Biomarkers in Cardiac AmyloidosisArianna Pregenzer-Wenzler, Jo Abraham, Kelsey Barrell, et al.
Transplantation Proceedings|August 3, 2024
The 90-Day Risk of Hospitalization in Heart Transplant Recipients After COVID-19 InfectionShriya Sharma, Jose Ruiz, Jose Nativi, et al.
Journal of Cardiac Failure|November 18, 2022
Rohan Goswami, Jose Ruiz, Jose Nativi, et al.
Current Problems in Cardiology|January 10, 2022
Diagnostic Tools for Cardiac Amyloidosis: A Pragmatic Comparison of Pathology, Imaging and LaboratoriesAbdulaziz Joury, Christian Faaborg-Andersen, Raymundo A Quintana, et al.
Orphanet Journal of Rare Diseases|October 4, 2021
Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progressionDavid Adams, Vincent Algalarrondo, Michael Polydefkis, et al.
Pageof 8

Showing results (1-10 of 80) with videos related to

Sort By:
Pageof 8
Circulation. Heart Failure|February 17, 2018
Serum Transthyretin: Predictor of Amyloidosis Outcomes?Jose Nativi-Nicolau
Current Opinion in Cardiology|July 18, 2018
Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common typesJose Nativi-Nicolau, Mathew S Maurer
Heart Failure Clinics|July 1, 2014
Current therapeutic approach in heart failure with preserved ejection fractionJose Nativi-Nicolau, John J Ryan, James C Fang
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|March 30, 2022
Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid CardiomyopathyMark H Rozenbaum, Diana Tran, Rahul Bhambri, et al.
Current Opinion in Cardiology|April 2, 2014
Pharmacologic therapies for acute cardiogenic shockJose Nativi-Nicolau, Craig H Selzman, James C Fang, et al.
JACC. Heart Failure|July 13, 2020
Utility of Biomarkers in Cardiac AmyloidosisArianna Pregenzer-Wenzler, Jo Abraham, Kelsey Barrell, et al.
Transplantation Proceedings|August 3, 2024
The 90-Day Risk of Hospitalization in Heart Transplant Recipients After COVID-19 InfectionShriya Sharma, Jose Ruiz, Jose Nativi, et al.
Journal of Cardiac Failure|November 18, 2022
Rohan Goswami, Jose Ruiz, Jose Nativi, et al.
Current Problems in Cardiology|January 10, 2022
Diagnostic Tools for Cardiac Amyloidosis: A Pragmatic Comparison of Pathology, Imaging and LaboratoriesAbdulaziz Joury, Christian Faaborg-Andersen, Raymundo A Quintana, et al.
Orphanet Journal of Rare Diseases|October 4, 2021
Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progressionDavid Adams, Vincent Algalarrondo, Michael Polydefkis, et al.
Pageof 8